• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

关于吡格列酮能减少大血管事件的证据在多大程度上支持了研究人员的说法？

How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events?

作者信息

Freemantle Nick

机构信息

University of Birmingham, Birmingham B15 2TT.

出版信息

BMJ. 2005 Oct 8;331(7520):836-8. doi: 10.1136/bmj.331.7520.836.

DOI:10.1136/bmj.331.7520.836
PMID:16210286
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1246089/
Abstract

Recent claims that pioglitazone prevents macrovascular events are based on a secondary outcome measure. But ignoring the primary outcome is statistically unsound

摘要

最近有关吡格列酮可预防大血管事件的说法是基于次要结局指标。但忽视主要结局在统计学上是不合理的。

相似文献

1
How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events?关于吡格列酮能减少大血管事件的证据在多大程度上支持了研究人员的说法？
BMJ. 2005 Oct 8;331(7520):836-8. doi: 10.1136/bmj.331.7520.836.
2
Glitazones in type 2 diabetes: an update.噻唑烷二酮类药物治疗2型糖尿病的研究进展
Drug Ther Bull. 2008 Apr;46(4):25-9. doi: 10.1136/dtb.2008.03.0008.
3
[Macrovascular secondary prevention with pioglitazone in diabetics. PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events)].吡格列酮用于糖尿病患者的大血管二级预防。前瞻性吡格列酮大血管事件临床试验（PROactive研究）
Internist (Berl). 2007 Jan;48(1):89-90; discussion 90-1. doi: 10.1007/s00108-006-1777-6.
4
[How does the PROactive Study change therapy of diabetes?].[PROactive研究如何改变糖尿病治疗？]
MMW Fortschr Med. 2005 Oct 13;147(41):6.
5
[Prospective pioglitazone clinical trial in macrovascular events].吡格列酮对大血管事件影响的前瞻性临床试验
Nihon Rinsho. 2012 May;70 Suppl 3:301-8.
6
[Insulin resistance and atherosclerosis. Controlling diabetes on 2 fronts].[胰岛素抵抗与动脉粥样硬化。从两方面控制糖尿病]
MMW Fortschr Med. 2003 Sep 11;145(37):65.
7
The clinical implications of the CHICAGO study for the management of cardiovascular risk in patients with type 2 diabetes mellitus.CHICAGO研究对2型糖尿病患者心血管风险管理的临床意义。
Trends Cardiovasc Med. 2009 Apr;19(3):94-9. doi: 10.1016/j.tcm.2009.06.002.
8
Intensive glucose lowering treatment in type 2 diabetes.2型糖尿病的强化降糖治疗
BMJ. 2011 Jul 26;343:d4243. doi: 10.1136/bmj.d4243.
9
Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20).吡格列酮与同时接受硝酸盐、肾素-血管紧张素系统阻滞剂或胰岛素治疗的 2 型糖尿病患者心血管事件风险：来自 PROactive 研究（PROactive 20）的结果。
J Diabetes. 2010 Sep;2(3):212-20. doi: 10.1111/j.1753-0407.2010.00082.x.
10
[Insulin sensitizers is now approved as monotherapy as well. Lowering blood pressure with added effects].
MMW Fortschr Med. 2003 Oct 9;145(41):47.

引用本文的文献

1
Midcourse correction to a clinical trial when the event rate is underestimated: the Look AHEAD (Action for Health in Diabetes) Study.当事件发生率被低估时，临床试验的中途校正：Look AHEAD（糖尿病中的健康行动）研究。
Clin Trials. 2012 Feb;9(1):113-24. doi: 10.1177/1740774511432726.
2
Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial.噻唑烷二酮与维生素 D 评估（TIDE）随机对照试验的设计、历史和结果。
Diabetologia. 2012 Jan;55(1):36-45. doi: 10.1007/s00125-011-2357-4. Epub 2011 Oct 29.
3
Overviews of pathogen emergence: which pathogens emerge, when and why?病原体出现的概述：哪些病原体出现、何时出现以及为何出现？
Curr Top Microbiol Immunol. 2007;315:85-111. doi: 10.1007/978-3-540-70962-6_5.
4
Insulin resistance and the metabolic syndrome--or the pitfalls of epidemiology.胰岛素抵抗与代谢综合征——或流行病学的陷阱
Diabetologia. 2007 Aug;50(8):1576-86. doi: 10.1007/s00125-007-0711-3. Epub 2007 Jun 26.
5
Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: what does evidence from randomised trials show about celecoxib?
BMJ. 2005 Dec 17;331(7530):1474-5. doi: 10.1136/bmj.331.7530.1474-c.
6
ASCOT: a tale of two treatment regimens: odds are that it's hype.ASCOT：两种治疗方案的故事：很可能只是炒作。
BMJ. 2005 Oct 29;331(7523):1022-3. doi: 10.1136/bmj.331.7523.1022-b.

本文引用的文献

1
Composite outcomes in randomized trials: greater precision but with greater uncertainty?随机试验中的复合结局：更高的精确性但伴随着更大的不确定性？
JAMA. 2003 May 21;289(19):2554-9. doi: 10.1001/jama.289.19.2554.
2
Interpreting the results of secondary end points and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic?解读临床试验中次要终点和亚组分析的结果：我们应该把疯姨妈锁在阁楼里吗？
BMJ. 2001 Apr 21;322(7292):989-91. doi: 10.1136/bmj.322.7292.989.
3
Carvedilol and the Food and Drug Administration (FDA) approval process: the FDA paradigm and reflections on hypothesis testing.卡维地洛与美国食品药品监督管理局（FDA）审批流程：FDA范式及对假设检验的思考
Control Clin Trials. 1999 Feb;20(1):16-39. doi: 10.1016/s0197-2456(98)00054-3.